LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Book: Lost in translation

    Srivastava, Rakesh / Maksymowicz, Wojciech / Lopaczynski, Wlodek

    barriers to incentives for translational research in medical sciences

    2014  

    Author's details ed. Rakesh Srivastava ; Wojciech Maksymowicz ; Wlodek Lopaczynski
    Keywords Translational Medical Research
    Language English
    Size XXIV, 741 S. : Ill., graph. Darst.
    Publisher World Scientific
    Publishing place Singapore
    Publishing country United States
    Document type Book
    Note Includes bibliographical references and index
    HBZ-ID HT018171888
    ISBN 978-981-4489-06-5 ; 981-4489-06-9
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2014 A 1687 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Translational research and behavioral sciences in developmental medicine: metabolic conditions of pregnancy versus autism spectrum disorders.

    Lopaczynski, Wlodek

    Medycyna wieku rozwojowego

    2012  Volume 16, Issue 3, Page(s) 171–174

    Abstract: Recently, scientific literature informed that metabolic conditions in pregnant women may be associated with increased risk for autism and other neurodevelopmental disorders in their offspring. In a cohort study of more than 1000 children between the ages ...

    Abstract Recently, scientific literature informed that metabolic conditions in pregnant women may be associated with increased risk for autism and other neurodevelopmental disorders in their offspring. In a cohort study of more than 1000 children between the ages of 2 and 5 years, those who had mothers classified as having "metabolic conditions" (which included diabetes, hypertension, and obesity) during pregnancy were at a significantly higher risk for developing an autism spectrum disorder (ASD) and neurodevelopmental delays. In addition, mothers with obesity were 1.6 times more likely to have a child with ASD and more than twice as likely to have a child with other developmental problems. In the United States, the prevalence of obesity among women of childbearing age is 34%. Moreover, with obesity rates rising steadily, these results appear to raise serious public health implications. The main objective of this Editorial is to propagate the health care improvement based on the translation research approach from basic behavioral sciences and relevant integrative neuroscience to pressing clinical issues that include an understanding of the etiology and assessment of disorders, and the assessment of functioning and development of innovative and culturally appropriate preventive treatment. Behavioral interventions for weight management in pregnancy may include the Transtheoretical Model (TTM) employed in obese pregnant women and then, the comparison with elements of the ecological model. A comparative effectiveness design is to test the effect of tailoring while including one of the most important predictors of screening-physician recommendation: after careful selection of analyzed behaviors from the TTM approach. However, there is also a risk that the evidence may not be conclusive for sustained weigh loss as a primary outcome of the proposed intervention, although the TTM in combination of physical activity and diet tended to produce significant results. Therefore, physicians might use the TTM to convince pregnant women to regulate weight and educate future parents on how to deal with autism at an early age of their children using watchful waiting management.
    MeSH term(s) Adult ; Behavioral Sciences ; Causality ; Child Development Disorders, Pervasive/epidemiology ; Child, Preschool ; Diabetes, Gestational/epidemiology ; Female ; Humans ; Hypertension/epidemiology ; Obesity/epidemiology ; Obesity/prevention & control ; Pregnancy ; Pregnancy Complications/epidemiology ; Pregnancy Complications/prevention & control ; Pregnancy in Diabetics/epidemiology ; Prenatal Exposure Delayed Effects/epidemiology ; Translational Medical Research
    Language English
    Publishing date 2012-07
    Publishing country Poland
    Document type Editorial
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Book: Lost in translation

    Srivastava, Rakesh K / Maksymowicz, Wojciech / Lopaczynski, Wlodek

    barriers to incentives for translational research in medical sciences

    2014  

    Author's details editors, Rakesh Srivastava, Wojciech Maksymowicz, Wlodek Lopaczynski
    MeSH term(s) Translational Medical Research
    Language English
    Size xxiv, 741 pages :, illustrations
    Document type Book
    ISBN 9789814489065 ; 9814489069
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article: Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.

    Cox, Josephine H / Ferrari, Guido / Kalams, Spyros A / Lopaczynski, Wlodek / Oden, Neal / D'souza, M Patricia

    AIDS research and human retroviruses

    2005  Volume 21, Issue 1, Page(s) 68–81

    Abstract: We used an external quality assurance (EQA) panel to assess laboratory competency and comparability when performing ELISPOT assays in support of human immunodeficiency virus type 1 (HIV-1) vaccine trials. Cell recovery, viability, and frequency of ... ...

    Abstract We used an external quality assurance (EQA) panel to assess laboratory competency and comparability when performing ELISPOT assays in support of human immunodeficiency virus type 1 (HIV-1) vaccine trials. Cell recovery, viability, and frequency of interferon-gamma (IFN-gamma)-secreting cells after antigen stimulation were obtained from 11 laboratories on a coded panel of 11 peripheral blood mononuclear cell samples. The median recovery and viability before plating for all samples were 35% and 86%, respectively, with notable interlaboratory and intrasample variability. Empirical as well as statistical analysis methods were used to define positive ELISPOT responses. Remarkable concordance between laboratories was obtained in defining a qualitative assessment of responder/nonresponder status to antigens, but the frequency of responding cells varied among the laboratories. This study highlights the need for better standardization of protocols and reagents to obtain reliable and reproducible data that may support immunogenicity studies, vaccine regulatory submissions, and licensure.
    MeSH term(s) AIDS Vaccines/administration & dosage ; AIDS Vaccines/immunology ; Clinical Trials as Topic ; Enzyme-Linked Immunosorbent Assay ; HIV Infections/prevention & control ; HIV-1/immunology ; Humans ; Interferon-gamma/secretion ; Laboratories ; Leukocytes, Mononuclear/immunology ; Lymphocyte Activation ; Quality Control ; Reproducibility of Results
    Chemical Substances AIDS Vaccines ; Interferon-gamma (82115-62-6)
    Language English
    Publishing date 2005-01
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 639130-8
    ISSN 1931-8405 ; 0889-2229
    ISSN (online) 1931-8405
    ISSN 0889-2229
    DOI 10.1089/aid.2005.21.68
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1928: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer.

    Miltyk, Woytek / Craciunescu, Corneliu N / Fischer, Leslie / Jeffcoat, Robert A / Koch, Matthew A / Lopaczynski, Wlodek / Mahoney, Chrysa / Crowell, James / Paglieri, Jennifer / Zeisel, Steven H

    The American journal of clinical nutrition

    2003  Volume 77, Issue 4, Page(s) 875–882

    Abstract: Background: Genistein may be useful in the prevention or treatment of prostate cancer; however, it causes genetic damage in cultured human cells.: Objective: The objective was to assess the potential genotoxicity of a purified soy unconjugated ... ...

    Abstract Background: Genistein may be useful in the prevention or treatment of prostate cancer; however, it causes genetic damage in cultured human cells.
    Objective: The objective was to assess the potential genotoxicity of a purified soy unconjugated isoflavone mixture in men with prostate cancer.
    Design: Twenty patients with prostate cancer were treated with 300 mg genistein/d for 28 d and then with 600 mg/d for another 56 d. In peripheral lymphocytes, DNA strand breaks were assessed as nuclear tail moment, chromosomal damage was assessed as micronucleus frequency (MF), and translocations of the MLL gene (11q23) were assessed by using fluorescence in situ hybridization. Values are also reported for 6 healthy men. The studies were performed under Investigational New Drug application no. 54 137 at a tertiary referral academic medical center.
    Results: No changes in group average or individual nuclear tail moment and MF were observed. We observed a single elevated MF value in one subject that exceeded a clinical threshold set before we initiated the study. A significant decrease in average COMET tail moment was observed on day 28 relative to day 0. We detected no genistein-induced rearrangements of the MLL gene in the 3 subjects we studied with this technique. MF increased significantly in lymphocytes exposed in vitro to unconjugated genistein at concentrations > or = 100 micromol/L. Total genistein never exceeded a peak concentration of 27.1 micro mol/L, and unconjugated genistein never exceeded a peak concentration of 0.32 micromol/L.
    Conclusion: Although isoflavones are capable of inducing genetic damage in vitro, a similar effect was not observed in subjects treated with a purified soy unconjugated isoflavone mixture.
    MeSH term(s) Adult ; Cells, Cultured ; Comet Assay ; DNA Damage/drug effects ; DNA-Binding Proteins/genetics ; Gene Deletion ; Genistein/adverse effects ; Genistein/blood ; Genistein/therapeutic use ; Histone-Lysine N-Methyltransferase ; Humans ; In Situ Hybridization, Fluorescence ; Isoflavones/administration & dosage ; Isoflavones/adverse effects ; Isoflavones/therapeutic use ; Lymphocytes/chemistry ; Lymphocytes/ultrastructure ; Male ; Micronuclei, Chromosome-Defective/ultrastructure ; Myeloid-Lymphoid Leukemia Protein ; Prostatic Neoplasms/drug therapy ; Proto-Oncogenes ; Glycine max/chemistry ; Transcription Factors ; Translocation, Genetic
    Chemical Substances DNA-Binding Proteins ; Isoflavones ; KMT2A protein, human ; Transcription Factors ; Myeloid-Lymphoid Leukemia Protein (149025-06-9) ; daidzein (6287WC5J2L) ; glycitein (92M5F28TVF) ; Genistein (DH2M523P0H) ; Histone-Lysine N-Methyltransferase (EC 2.1.1.43)
    Language English
    Publishing date 2003-03-26
    Publishing country United States
    Document type Clinical Trial ; Clinical Trial, Phase I ; Journal Article ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 280048-2
    ISSN 1938-3207 ; 0002-9165
    ISSN (online) 1938-3207
    ISSN 0002-9165
    DOI 10.1093/ajcn/77.4.875
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ue I Zs.208: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women.

    Bloedon, LeAnne T / Jeffcoat, A Robert / Lopaczynski, Wlodek / Schell, Michael J / Black, Tracy M / Dix, Kelly J / Thomas, Brian F / Albright, Craig / Busby, Marjorie G / Crowell, James A / Zeisel, Steven H

    The American journal of clinical nutrition

    2002  Volume 76, Issue 5, Page(s) 1126–1137

    Abstract: Background: Soy isoflavones are being evaluated as chemopreventive agents for breast and other cancers.: Objective: The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, ...

    Abstract Background: Soy isoflavones are being evaluated as chemopreventive agents for breast and other cancers.
    Objective: The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal women.
    Design: Twenty-four healthy postmenopausal women ingested a single dose of 1 of 2 purified (from soybeans) isoflavone preparations that delivered a genistein dose of 2, 4, 8, or 16 mg/kg body wt. These doses were higher than those previously administered to human females. Toxicity studies were performed 24 h and 3, 6, 14, and 30 d after isoflavone administration. Kinetic studies were performed during the first 24 h.
    Results: We observed a 7% decrease in systolic and diastolic blood pressure and a 32% decrease in the neutrophil count 24 h after treatment with formulation A. Isolated episodes of nausea, pedal edema, and breast tenderness were judged to be possibly related to the study treatment. The terminal plasma half-lives for free genistein, daidzein, and glycitein averaged 3.8, 7.7, and 3.4 h, respectively. The terminal pseudo half-lives for total genistein and total daidzein in plasma averaged 10.1 and 10.8 h, respectively. The estimated bioavailabilities of both total genistein and total daidzein from each of the 2 formulations were not significantly different.
    Conclusions: A single-dose administration of purified unconjugated isoflavones at amounts that exceed normal dietary intakes had minimal clinical toxicity in healthy postmenopausal women. The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones.
    MeSH term(s) Aged ; Blood Pressure/drug effects ; Dose-Response Relationship, Drug ; Drug Combinations ; Female ; Genistein/blood ; Genistein/urine ; Half-Life ; Humans ; Isoflavones/administration & dosage ; Isoflavones/adverse effects ; Isoflavones/blood ; Isoflavones/pharmacokinetics ; Isoflavones/pharmacology ; Isoflavones/urine ; Middle Aged ; Postmenopause/drug effects ; Postmenopause/metabolism ; Glycine max/chemistry
    Chemical Substances Drug Combinations ; Isoflavones ; daidzein (6287WC5J2L) ; glycitein (92M5F28TVF) ; Genistein (DH2M523P0H)
    Language English
    Publishing date 2002-09-28
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
    ZDB-ID 280048-2
    ISSN 1938-3207 ; 0002-9165
    ISSN (online) 1938-3207
    ISSN 0002-9165
    DOI 10.1093/ajcn/76.5.1126
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ue I Zs.208: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women

    Bloedon, LeAnne T / Jeffcoat, A. Robert / Lopaczynski, Wlodek / Schell, Michael J / Black, Tracy M / Dix, Kelly J / Thomas, Brian F / Albright, Craig / Busby, Marjorie G / Crowell, James A / Zeisel, Steven H

    American journal of clinical nutrition. 2002 Nov., v. 76, no. 5

    2002  

    Abstract: Background: Soy isoflavones are being evaluated as chemopreventive agents for breast and other cancers. Objective: The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, ... ...

    Abstract Background: Soy isoflavones are being evaluated as chemopreventive agents for breast and other cancers. Objective: The objective was to perform safety and pharmacokinetic studies of purified unconjugated isoflavone preparations containing genistein, daidzein, and glycitein in postmenopausal women. Design: Twenty-four healthy postmenopausal women ingested a single dose of 1 of 2 purified (from soybeans) isoflavone preparations that delivered a genistein dose of 2, 4, 8, or 16 mg/kg body wt. These doses were higher than those previously administered to human females. Toxicity studies were performed 24 h and 3, 6, 14, and 30 d after isoflavone administration. Kinetic studies were performed during the first 24 h. Results: We observed a 7% decrease in systolic and diastolic blood pressure and a 32% decrease in the neutrophil count 24 h after treatment with formulation A. Isolated episodes of nausea, pedal edema, and breast tenderness were judged to be possibly related to the study treatment. The terminal plasma half-lives for free genistein, daidzein, and glycitein averaged 3.8, 7.7, and 3.4 h, respectively. The terminal pseudo half-lives for total genistein and total daidzein in plasma averaged 10.1 and 10.8 h, respectively. The estimated bioavailabilities of both total genistein and total daidzein from each of the 2 formulations were not significantly different. Conclusions: A single-dose administration of purified unconjugated isoflavones at amounts that exceed normal dietary intakes had minimal clinical toxicity in healthy postmenopausal women. The pharmacokinetic data suggest that chronic dosing at 12-24-h intervals would not lead to progressive accumulation of these isoflavones.
    Keywords bioavailability ; daidzein ; diastolic blood pressure ; edema ; females ; genistein ; glycitein ; half life ; nausea ; neoplasms ; pharmacokinetics ; postmenopause ; soybeans ; toxicity ; toxicity testing ; women
    Language English
    Dates of publication 2002-11
    Size p. 1126-1137.
    Document type Article
    ZDB-ID 280048-2
    ISSN 1938-3207 ; 0002-9165
    ISSN (online) 1938-3207
    ISSN 0002-9165
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    In stock of ZB MED Bonn / Germany

    Z 72/516: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top